论文部分内容阅读
目的:对RANKL/RANK通路在乳腺癌发生演进中的作用及研究进展简要总结和评述。方法:以乳腺癌和核因子Kβ受体活化因子配体(or RANKL)为关键词,检索1997-01-2011-02 PubMed、CNKI和维普数据库的相关文献。纳入标准:1)RANKL/RANK通路表达及功能2)RANKL/RANK通路与乳腺癌的文献。根据纳入标准纳入分析文献31篇。结果:RANKL/RANK通路不仅影响孕期乳腺的的发育,近年来的研究相继发现RANKL/RANK通路参与了女性性激素相关乳腺癌的发生;同时RANKL与RANK间的相互作用促进了乳腺癌细胞的迁移和存活,从而介导乳腺癌细胞的转移过程。针对RANKL人单抗denosumab在乳腺癌治疗的临床研究已经逐步开展。结论:以RANKL/RANK为靶点的治疗有望成为乳腺癌预防和治疗新的方法。
Objective: To summarize and review the role of RANKL / RANK pathway in the development of breast cancer and its research progress. METHODS: The relevant literature of PubMed, CNKI and VIP databases was searched from January 1997 to November 2011 with breast cancer and or RANKL as the key words. Inclusion criteria: 1) RANKL / RANK pathway expression and function 2) RANKL / RANK pathway and breast cancer literature. According to inclusion criteria, 31 articles were included in the analysis. Results: The RANKL / RANK pathway not only affected the development of mammary gland during pregnancy. Recent studies have found that RANKL / RANK pathway is involved in the development of female sex hormone-related breast cancer. Meanwhile, the interaction between RANKL and RANK promotes the migration of breast cancer cells and Survival, which mediated breast cancer cell metastasis process. Clinical research on the treatment of breast cancer with RANKL human monoclonal antibody denosumab has been gradually carried out. Conclusion: The treatment of RANKL / RANK target is expected to become a new method of prevention and treatment of breast cancer.